Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Alexander Olawaiye; Laurence Gladieff; David M. O’Malley; Jae‐Weon Kim; Gabriel Garbaos; Vanda Salutari; Lucy Gilbert; Linda Mileshkin; Alix Devaux; Elizabeth Hopp; Yong Jae Lee; Ana Oaknin; Mariana Scaranti; Byoung-Gie Kim; Nicoletta Colombo; Michael McCollum; Connie I. Diakos; Andrew R. Clamp; Aliza Leiser; Boglárka Balázs; Bradley J. Monk; Giuseppa Scandurra; C. McClung; Emilie Kaczmarek; Brian M. Slomovitz; Helena de la Cueva; Aknar Calabrich; Chiara Cassani; Benoît You; Toon Van Gorp; Cristina Churruca; Giuseppe Luigi Banna; Shibani Nicum; Andrea Bagaméri; Grazia Artioli; Lubomir Bodnar; Sokbom Kang; Ignace Vergote; Amanda Kesner-Hays; Hristina I. Pashova; Sachin Gopalkrishna Pai; Iulia Cristina Tudor; Adrian M. Jubb; Domenica Lorusso

doi:10.1016/s0140-6736(25)01040-2

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Alexander Olawaiye(Magee-Womens Hospital), Laurence Gladieff(Institut Claudius Regaud), David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jae‐Weon Kim(Seoul National University), Gabriel Garbaos(Fundación Centro de Estudios Infectológicos), Vanda Salutari(Agostino Gemelli University Polyclinic), Lucy Gilbert(McGill University Health Centre), Linda Mileshkin(Peter MacCallum Cancer Centre), Alix Devaux(Hôpital Civil de Charleroi), Elizabeth Hopp(Medical College of Wisconsin), Yong Jae Lee(Yonsei University), Ana Oaknin(Vall d'Hebron Hospital Universitari), Mariana Scaranti, Byoung-Gie Kim(Samsung Medical Center), Nicoletta Colombo(European Institute of Oncology), Michael McCollum(Virginia Oncology Associates), Connie I. Diakos(Royal North Shore Hospital), Andrew R. Clamp(Manchester University NHS Foundation Trust), Aliza Leiser(Rutgers, The State University of New Jersey), Boglárka Balázs(National Institute of Oncology), Bradley J. Monk(Florida Cancer Specialists & Research Institute), Giuseppa Scandurra(Università degli Studi di Enna Kore), C. McClung(Palo Alto University), Emilie Kaczmarek(Centre Oscar Lambret), Brian M. Slomovitz(Mount Sinai Medical Center), Helena de la Cueva(Leitat Technological Center), Aknar Calabrich(European Telecommunications Standards Institute), Chiara Cassani(University of Pavia), Benoît You(Hospices Civils de Lyon), Toon Van Gorp(The European Academy of Gynaecological Surgery), Cristina Churruca(Biogipuzkoa Health Research Institute), Giuseppe Luigi Banna(European Institute of Oncology), Shibani Nicum(University College Hospital), Andrea Bagaméri(National Institute of Oncology), Grazia Artioli(AULSS 2 Marca Trevigiana), Lubomir Bodnar(University of Siedlce), Sokbom Kang(National Cancer Center), Ignace Vergote(KU Leuven), Amanda Kesner-Hays(Corcept Therapeutics (United States)), Hristina I. Pashova(Corcept Therapeutics (United States)), Sachin Gopalkrishna Pai(Corcept Therapeutics (United States)), Iulia Cristina Tudor(Corcept Therapeutics (United States)), Adrian M. Jubb(Corcept Therapeutics (United States)), Domenica Lorusso(Humanitas University)

The Lancet

June 1, 2025

10.1016/s0140-6736(25)01040-2

Cited by 41

Abstract

Related Papers

No related papers found

Powered by citation graph analysis